Radiopharm Theranostics Advances RAD 101 into Phase 3 After Strong Phase 2b Results — Radiopharm Theranostics Limited

Event summary

Radiopharm Theranostics reported 93% of patients in Phase 2b trial of RAD 101 achieved primary endpoint.
Company plans to initiate Phase 3 registrational trial for RAD 101 in Q4 2026.
Raised $12.5M through institutional offer and launched $6M Share Purchase Plan post-quarter.
Early clinical signs show RECIST-confirmed Partial Response in first patient treated with RAD 204 at new dose level.

The big picture

Radiopharm Theranostics is positioning itself as a leader in targeted radiopharmaceuticals for oncology, with RAD 101's progress marking a critical step toward commercialization. The company's ability to secure non-dilutive funding through the Australian R&D Tax Incentive and institutional offerings underscores investor confidence in its pipeline. Success in Phase 3 could validate the company's platform approach across multiple cancer indications.

What we're watching

Regulatory Pathway: Whether RAD 101's Phase 3 trial will maintain momentum and secure FDA approval.
Clinical Validation: How RAD 204's early partial response data translates into broader efficacy across multiple cancer types.
Financial Runway: The pace at which Radiopharm Theranostics can extend its cash position through additional funding rounds.